Anti-VEGF injections may be associated with acute IOP spikes and chronic IOP rise in patients, and these increases in IOP need to be acknowledged and managed, according to Matthew Schlenker MD, MSc.
Day 3 of the 2019 annual meeting of the American Academy of Ophthalmology features Fernando Arevalo, MD, FACS, as he shares findings from his presentation on using brolucizumab to treat neovascular age-related macular degeneration (AMD),
According to Jeffrey Heier, MD, RGX-314 administered by subretinal injection was well tolerated. In addition, it was associated with dose-dependent increase in ocular protein expression and evidence of clinical benefit.
The MDA is a nonprofit health organization dedicated to educating and empowering patients with AMD.